Clinical Trial Results: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial results for a recombinant vaccinia virus in combination with cemiplimab in renal cell carcinoma have been completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Cemiplimab (cemiplimab)
• Recombinant Vaccinia Virus

Snippet

Sponsor: SillaJen, Inc. | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-06-18